402 related articles for article (PubMed ID: 26371289)
1. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis.
Brkic Z; van Bon L; Cossu M; van Helden-Meeuwsen CG; Vonk MC; Knaapen H; van den Berg W; Dalm VA; Van Daele PL; Severino A; Maria NI; Guillen S; Dik WA; Beretta L; Versnel MA; Radstake T
Ann Rheum Dis; 2016 Aug; 75(8):1567-73. PubMed ID: 26371289
[TBL] [Abstract][Full Text] [Related]
2. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression.
Brkic Z; Maria NI; van Helden-Meeuwsen CG; van de Merwe JP; van Daele PL; Dalm VA; Wildenberg ME; Beumer W; Drexhage HA; Versnel MA
Ann Rheum Dis; 2013 May; 72(5):728-35. PubMed ID: 22736090
[TBL] [Abstract][Full Text] [Related]
4. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.
York MR; Nagai T; Mangini AJ; Lemaire R; van Seventer JM; Lafyatis R
Arthritis Rheum; 2007 Mar; 56(3):1010-20. PubMed ID: 17328080
[TBL] [Abstract][Full Text] [Related]
5. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
6. The Long Non-coding RNA NRIR Drives IFN-Response in Monocytes: Implication for Systemic Sclerosis.
Mariotti B; Servaas NH; Rossato M; Tamassia N; Cassatella MA; Cossu M; Beretta L; van der Kroef M; Radstake TRDJ; Bazzoni F
Front Immunol; 2019; 10():100. PubMed ID: 30804934
[TBL] [Abstract][Full Text] [Related]
7. Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis.
Yin H; Distler O; Shen L; Xu X; Yuan Y; Li R; Liu B; Li Q; Huang Q; Xie F; Zhang Z; Liang R; Dai X; Chen X; Li B; Yan Q; Lu L
Arthritis Rheumatol; 2024 Jan; 76(1):78-91. PubMed ID: 37488975
[TBL] [Abstract][Full Text] [Related]
8. Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum.
Cossu M; van Bon L; Preti C; Rossato M; Beretta L; Radstake TRDJ
Arthritis Rheumatol; 2017 Dec; 69(12):2359-2369. PubMed ID: 28859262
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes.
Matsushita T; Hasegawa M; Yanaba K; Kodera M; Takehara K; Sato S
Arthritis Rheum; 2006 Jan; 54(1):192-201. PubMed ID: 16385515
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N
Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
[TBL] [Abstract][Full Text] [Related]
11. Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic Sclerosis.
Vlachogiannis NI; Pappa M; Ntouros PA; Nezos A; Mavragani CP; Souliotis VL; Sfikakis PP
Front Immunol; 2020; 11():582401. PubMed ID: 33123169
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.
Farina A; Peruzzi G; Lacconi V; Lenna S; Quarta S; Rosato E; Vestri AR; York M; Dreyfus DH; Faggioni A; Morrone S; Trojanowska M; Farina GA
Arthritis Res Ther; 2017 Feb; 19(1):39. PubMed ID: 28245863
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis.
Rudnik M; Rolski F; Jordan S; Mertelj T; Stellato M; Distler O; Blyszczuk P; Kania G
Arthritis Rheumatol; 2021 Sep; 73(9):1720-1730. PubMed ID: 33760395
[TBL] [Abstract][Full Text] [Related]
14. Circulating Collagen Metabolites and the Enhanced Liver Fibrosis (ELF) Score as Fibrosis Markers in Systemic Sclerosis.
Chen C; Wang L; Wu J; Lu M; Yang S; Ye W; Guan M; Liang M; Zou H
Front Pharmacol; 2022; 13():805708. PubMed ID: 35177989
[No Abstract] [Full Text] [Related]
15. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF.
Matsushita T; Fujimoto M; Hasegawa M; Tanaka C; Kumada S; Ogawa F; Takehara K; Sato S
J Rheumatol; 2007 Oct; 34(10):2056-62. PubMed ID: 17896803
[TBL] [Abstract][Full Text] [Related]
16. Profibrotic Activation of Human Macrophages in Systemic Sclerosis.
Bhandari R; Ball MS; Martyanov V; Popovich D; Schaafsma E; Han S; ElTanbouly M; Orzechowski NM; Carns M; Arroyo E; Aren K; Hinchcliff M; Whitfield ML; Pioli PA
Arthritis Rheumatol; 2020 Jul; 72(7):1160-1169. PubMed ID: 32134204
[TBL] [Abstract][Full Text] [Related]
17. Elevated procollagen type I carboxyterminal propeptide production in cultured scleroderma fibroblasts.
Kikuchi K; Kadono T; Fujimoto M; Ihn H; Sato S; Takehara K
Dermatology; 1995; 190(2):104-8. PubMed ID: 7727830
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Long Non-Coding RNAs in Systemic Sclerosis Monocytes: A Potential Role for PSMB8-AS1 in Altered Cytokine Secretion.
Servaas NH; Mariotti B; van der Kroef M; Wichers CGK; Pandit A; Bazzoni F; Radstake TRDJ; Rossato M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922041
[TBL] [Abstract][Full Text] [Related]
19. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis.
Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
Exp Dermatol; 2016 Apr; 25(4):287-92. PubMed ID: 26661692
[TBL] [Abstract][Full Text] [Related]
20. The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis.
Zhou Y; Hou W; Xu K; Han D; Jiang C; Mou K; Li Y; Meng L; Lu S
Hum Immunol; 2015 Jan; 76(1):22-9. PubMed ID: 25500255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
